Judge Ruled Against Alkermes in Vivitrol Patent Case
A Massachusetts federal judge denied a motion to dismiss a class-action lawsuit challenging addiction drug patent claims.
Updated on Sept. 25, 2026 in Substance Abuse
Live Poll
Should pharmaceutical companies face legal accountability for alleged misconduct in the patent application process?
A federal judge in Massachusetts has denied a motion from Alkermes to dismiss a proposed class-action lawsuit. The litigation alleges the company misled the U.S. Patent and Trademark Office to secure a patent for its addiction treatment drug, Vivitrol.
Why it matters
The outcome of this litigation could have significant implications for patent transparency and the regulatory approval processes surrounding addiction medications. It highlights ongoing legal scrutiny regarding how pharmaceutical companies obtain and protect intellectual property for widely used therapies.
A federal court ruling denied a motion to dismiss a class-action complaint centered on allegations of intentional omission in a patent application. The litigation remains ongoing with the underlying claims yet to be proven in court.
The players
Alkermes
A pharmaceutical company that develops treatments for central nervous system disorders and addiction.
U.S. Patent and Trademark Office
The federal agency responsible for granting patents and protecting intellectual property rights.
The details
The lawsuit centers on the claim that Alkermes allegedly withheld a study from the U.S. Patent and Trademark Office to gain an advantage in the patent application process for Vivitrol. The court evaluated these specific allegations during the motion to dismiss phase. The decision allows the case to proceed toward discovery and further judicial review.
Timeline
September 24, 2026: A federal judge ruled on the motion to dismiss.
Health Landscape
This case sits within a broader legal trend of pharmaceutical companies facing increased scrutiny over the validity of drug patents. The lawsuit follows a pattern set by previous legal challenges involving the Hatch-Waxman Act drug patent provisions.
This legal development does not immediately change how patients receive care or access their prescriptions. Individuals managing substance use disorders with Vivitrol should continue their treatment plans and direct any questions about medication history to their prescribing physician.
The takeaway
The court's decision ensures that the allegations regarding the patent application process for Vivitrol will face further legal examination. Patients should continue focusing on their established treatment protocols and maintain regular communication with their healthcare providers.
Further reading
For more on the current state of addiction treatment accessibility, visit Substance Abuse.
Source note: This article includes information reported by Law360.
Live Poll
Should pharmaceutical companies face legal accountability for alleged misconduct in the patent application process?
